Vir Biotechnology, Inc. Operating Cash Flow
Vir Biotechnology, Inc. (VIR) reported Operating Cash Flow of -$9.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $123.33M.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$132.39M.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$25.88M.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$167.57M.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$391.78M.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$446.35M.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$778.78M, a 146.82% decline from fiscal 2022.
- Vir Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $1.66B.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $123.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$9.06M 10-Q · filed 2026-08-05 | -$34.94M derived: sum of 3 quarters · filed 2026-08-05 | -$202.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$132.39M 10-Q · filed 2026-05-07 | -$158.26M derived: sum of 2 quarters · filed 2026-05-07 | -$325.83M derived: sum of 3 quarters · filed 2026-05-07 | -$446.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$25.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$193.45M derived: sum of 2 quarters · filed 2026-02-23 | -$313.67M derived: sum of 3 quarters · filed 2026-08-05 | -$391.78M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$167.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$287.79M derived: sum of 2 quarters · filed 2026-08-05 | -$365.90M 10-Q · filed 2025-11-05 | -$453.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$120.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$198.34M 10-Q · filed 2026-08-05 | -$285.97M derived: sum of 3 quarters · filed 2026-08-05 | -$457.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$78.12M 10-Q · filed 2026-05-07 | -$165.75M derived: sum of 2 quarters · filed 2026-05-07 | -$337.23M derived: sum of 3 quarters · filed 2026-05-07 | -$415.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$87.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$259.12M derived: sum of 2 quarters · filed 2026-02-23 | -$336.96M derived: sum of 3 quarters · filed 2026-02-23 | -$446.35M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$171.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$249.33M derived: sum of 2 quarters · filed 2025-11-05 | -$358.72M 10-Q · filed 2025-11-05 | -$466.64M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$77.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$187.24M 10-Q · filed 2025-08-06 | -$295.16M derived: sum of 3 quarters · filed 2026-02-23 | -$450.99M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$109.39M 10-Q · filed 2025-05-08 | -$217.32M derived: sum of 2 quarters · filed 2026-02-23 | -$373.15M derived: sum of 3 quarters · filed 2026-02-23 | -$762.39M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$107.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$263.76M derived: sum of 2 quarters · filed 2026-02-23 | -$653.00M derived: sum of 3 quarters · filed 2026-02-23 | -$778.78M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$155.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$545.08M derived: sum of 2 quarters · filed 2024-11-04 | -$670.86M 10-Q · filed 2024-11-04 | -$635.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$389.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$515.03M 10-Q · filed 2024-08-01 | -$479.90M derived: sum of 3 quarters · filed 2025-02-27 | -$362.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$125.78M 10-Q · filed 2024-05-03 | -$90.66M derived: sum of 2 quarters · filed 2025-02-27 | $27.25M derived: sum of 3 quarters · filed 2025-02-27 | $987.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $35.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $153.03M derived: sum of 2 quarters · filed 2025-02-27 | $1.11B derived: sum of 3 quarters · filed 2025-02-27 | $1.66B 10-K · filed 2025-02-27 |
| 2022-09-30 | $117.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.08B derived: sum of 2 quarters · filed 2023-11-03 | $1.63B 10-Q · filed 2023-11-03 | $1.64B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $960.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.51B 10-Q · filed 2023-08-04 | $1.52B derived: sum of 3 quarters · filed 2024-02-26 | $1.41B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $550.09M 10-Q · filed 2023-05-08 | $557.78M derived: sum of 2 quarters · filed 2024-02-26 | $451.97M derived: sum of 3 quarters · filed 2024-02-26 | $592.03M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$98.12M derived: sum of 2 quarters · filed 2024-02-26 | $41.94M derived: sum of 3 quarters · filed 2024-02-26 | -$47.59M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$105.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $34.24M derived: sum of 2 quarters · filed 2022-11-03 | -$55.28M 10-Q · filed 2022-11-03 | -$137.34M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $140.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $50.53M 10-Q · filed 2022-08-09 | -$31.52M derived: sum of 3 quarters · filed 2023-02-28 | -$81.36M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$89.53M 10-Q · filed 2022-05-05 | -$171.58M derived: sum of 2 quarters · filed 2023-02-28 | -$221.42M derived: sum of 3 quarters · filed 2023-02-28 | -$232.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$82.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$131.89M derived: sum of 2 quarters · filed 2023-02-28 | -$142.53M derived: sum of 3 quarters · filed 2023-02-28 | -$190.94M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$49.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$60.48M derived: sum of 2 quarters · filed 2021-11-04 | -$108.89M 10-Q · filed 2021-11-04 | -$147.77M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$10.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$59.05M 10-Q · filed 2021-08-05 | -$97.93M derived: sum of 3 quarters · filed 2022-02-28 | -$134.89M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$48.41M 10-Q · filed 2021-05-06 | -$87.29M derived: sum of 2 quarters · filed 2022-02-28 | -$124.25M derived: sum of 3 quarters · filed 2022-02-28 | -$148.55M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$38.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$75.84M derived: sum of 2 quarters · filed 2022-02-28 | -$100.14M derived: sum of 3 quarters · filed 2022-02-28 | -$129.63M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$36.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$61.26M derived: sum of 2 quarters · filed 2020-11-10 | -$90.75M 10-Q · filed 2020-11-10 | -$120.25M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$24.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$53.79M 10-Q · filed 2020-08-11 | -$83.30M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$29.49M 10-Q · filed 2020-05-12 | -$59.00M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$29.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$94.10M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$64.59M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | -$66.38M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |